Entering the highly competitive obesity space, AbbVie has signed a license agreement with Gubra to develop GUB14295, a potential best-in-class, long-acting amylin analogue for the treatment of obesity. Through the deal, which involves a US$350 M upfront payment and up to US$1.875 B in milestone payments, the companies will build on the promising data already demonstrated in a Phase I single ascending dose trial. If successful, GUB14295 has the potential to compete with several other investigational amylin agonists being developed by key players such as Novo Nordisk, Lilly and Zealand Pharma.